Cargando…
A twelve‐week, four‐arm, randomized, double‐blind, placebo‐controlled, phase 2 prospective clinical trial to evaluate the efficacy and safety of an anthroposophic multimodal treatment on chronic pain in outpatients with postpolio syndrome
INTRODUCTION: Chronic pain and fatigue are the main symptoms of postpoliomyelitis syndrome (PPS). This study aimed to evaluate the efficacy and safety of an anthroposophic multimodal treatment for chronic pain in PPS outpatients. METHODS: A twelve‐week, four‐arm, randomized, double‐blind, placebo‐co...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177555/ https://www.ncbi.nlm.nih.gov/pubmed/32162497 http://dx.doi.org/10.1002/brb3.1590 |
_version_ | 1783525246005936128 |
---|---|
author | Ghelman, Ricardo Akiyama, Ivete Y. de Souza, Valeria T. Falcão, Jussara Orgolini, Vera Hosomi, Jorge K. Quadros, Abrahão A. J. Oliveira, Acary S. B. |
author_facet | Ghelman, Ricardo Akiyama, Ivete Y. de Souza, Valeria T. Falcão, Jussara Orgolini, Vera Hosomi, Jorge K. Quadros, Abrahão A. J. Oliveira, Acary S. B. |
author_sort | Ghelman, Ricardo |
collection | PubMed |
description | INTRODUCTION: Chronic pain and fatigue are the main symptoms of postpoliomyelitis syndrome (PPS). This study aimed to evaluate the efficacy and safety of an anthroposophic multimodal treatment for chronic pain in PPS outpatients. METHODS: A twelve‐week, four‐arm, randomized, double‐blind, placebo‐controlled, phase 2 prospective clinical trial was designed to compare four groups (n = 48): groups A and B received daily active experimental transdermal gel (ETG) or placebo gel (PTG), respectively; groups C and D received weekly external therapies, art therapies, and neurofunctional reorganization, plus either daily ETG or PTG, respectively. The pain symptoms were evaluated through a visual analogue scale (VAS), the McGill questionnaire, and thermography. Quality of life and resilience were evaluated by the WHOQOL‐BREF and Antonovsky sense of coherence questionnaires applied at baseline and after the interventions. RESULTS: No related adverse events occurred, and 10% of the patients reports dysphagia improvement. In the groups C and D, pain reduction was statistically significant in both the placebo group (p = .02, d = 1.315) and in the ETG (p = .005, d = 2.035). However, following the week‐to‐week evolution of pain with the concomitant use of the ETG, this significant pain reduction occurred earlier from the 4th week and continued to decrease (p = .016, d = 1.369). In the group that received the complete multimodal treatment, the greatest significant benefit in increasing quality of life occurred in the physical domain and elevation in resilience with an emphasis on meaning and comprehension domains. CONCLUSIONS: The anthroposophic multimodal treatment group presented both safety and efficacy as an analgesic in the groups that received the nonpharmacological therapies, much earlier when associated with the ETG. The multimodal approach corresponded to the pattern of better efficacy for both pain reduction and improvement in quality of life and resilience. |
format | Online Article Text |
id | pubmed-7177555 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71775552020-04-24 A twelve‐week, four‐arm, randomized, double‐blind, placebo‐controlled, phase 2 prospective clinical trial to evaluate the efficacy and safety of an anthroposophic multimodal treatment on chronic pain in outpatients with postpolio syndrome Ghelman, Ricardo Akiyama, Ivete Y. de Souza, Valeria T. Falcão, Jussara Orgolini, Vera Hosomi, Jorge K. Quadros, Abrahão A. J. Oliveira, Acary S. B. Brain Behav Original Research INTRODUCTION: Chronic pain and fatigue are the main symptoms of postpoliomyelitis syndrome (PPS). This study aimed to evaluate the efficacy and safety of an anthroposophic multimodal treatment for chronic pain in PPS outpatients. METHODS: A twelve‐week, four‐arm, randomized, double‐blind, placebo‐controlled, phase 2 prospective clinical trial was designed to compare four groups (n = 48): groups A and B received daily active experimental transdermal gel (ETG) or placebo gel (PTG), respectively; groups C and D received weekly external therapies, art therapies, and neurofunctional reorganization, plus either daily ETG or PTG, respectively. The pain symptoms were evaluated through a visual analogue scale (VAS), the McGill questionnaire, and thermography. Quality of life and resilience were evaluated by the WHOQOL‐BREF and Antonovsky sense of coherence questionnaires applied at baseline and after the interventions. RESULTS: No related adverse events occurred, and 10% of the patients reports dysphagia improvement. In the groups C and D, pain reduction was statistically significant in both the placebo group (p = .02, d = 1.315) and in the ETG (p = .005, d = 2.035). However, following the week‐to‐week evolution of pain with the concomitant use of the ETG, this significant pain reduction occurred earlier from the 4th week and continued to decrease (p = .016, d = 1.369). In the group that received the complete multimodal treatment, the greatest significant benefit in increasing quality of life occurred in the physical domain and elevation in resilience with an emphasis on meaning and comprehension domains. CONCLUSIONS: The anthroposophic multimodal treatment group presented both safety and efficacy as an analgesic in the groups that received the nonpharmacological therapies, much earlier when associated with the ETG. The multimodal approach corresponded to the pattern of better efficacy for both pain reduction and improvement in quality of life and resilience. John Wiley and Sons Inc. 2020-03-11 /pmc/articles/PMC7177555/ /pubmed/32162497 http://dx.doi.org/10.1002/brb3.1590 Text en © 2020 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Ghelman, Ricardo Akiyama, Ivete Y. de Souza, Valeria T. Falcão, Jussara Orgolini, Vera Hosomi, Jorge K. Quadros, Abrahão A. J. Oliveira, Acary S. B. A twelve‐week, four‐arm, randomized, double‐blind, placebo‐controlled, phase 2 prospective clinical trial to evaluate the efficacy and safety of an anthroposophic multimodal treatment on chronic pain in outpatients with postpolio syndrome |
title | A twelve‐week, four‐arm, randomized, double‐blind, placebo‐controlled, phase 2 prospective clinical trial to evaluate the efficacy and safety of an anthroposophic multimodal treatment on chronic pain in outpatients with postpolio syndrome |
title_full | A twelve‐week, four‐arm, randomized, double‐blind, placebo‐controlled, phase 2 prospective clinical trial to evaluate the efficacy and safety of an anthroposophic multimodal treatment on chronic pain in outpatients with postpolio syndrome |
title_fullStr | A twelve‐week, four‐arm, randomized, double‐blind, placebo‐controlled, phase 2 prospective clinical trial to evaluate the efficacy and safety of an anthroposophic multimodal treatment on chronic pain in outpatients with postpolio syndrome |
title_full_unstemmed | A twelve‐week, four‐arm, randomized, double‐blind, placebo‐controlled, phase 2 prospective clinical trial to evaluate the efficacy and safety of an anthroposophic multimodal treatment on chronic pain in outpatients with postpolio syndrome |
title_short | A twelve‐week, four‐arm, randomized, double‐blind, placebo‐controlled, phase 2 prospective clinical trial to evaluate the efficacy and safety of an anthroposophic multimodal treatment on chronic pain in outpatients with postpolio syndrome |
title_sort | twelve‐week, four‐arm, randomized, double‐blind, placebo‐controlled, phase 2 prospective clinical trial to evaluate the efficacy and safety of an anthroposophic multimodal treatment on chronic pain in outpatients with postpolio syndrome |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177555/ https://www.ncbi.nlm.nih.gov/pubmed/32162497 http://dx.doi.org/10.1002/brb3.1590 |
work_keys_str_mv | AT ghelmanricardo atwelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome AT akiyamaivetey atwelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome AT desouzavaleriat atwelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome AT falcaojussara atwelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome AT orgolinivera atwelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome AT hosomijorgek atwelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome AT quadrosabrahaoaj atwelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome AT oliveiraacarysb atwelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome AT ghelmanricardo twelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome AT akiyamaivetey twelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome AT desouzavaleriat twelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome AT falcaojussara twelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome AT orgolinivera twelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome AT hosomijorgek twelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome AT quadrosabrahaoaj twelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome AT oliveiraacarysb twelveweekfourarmrandomizeddoubleblindplacebocontrolledphase2prospectiveclinicaltrialtoevaluatetheefficacyandsafetyofananthroposophicmultimodaltreatmentonchronicpaininoutpatientswithpostpoliosyndrome |